Leap Therapeutics

#9985

Rank

$17.38M

Marketcap

United States

Country

Leadership team

Mr. Douglas E. Onsi J.D. (CFO, Gen. Counsel, Treasurer & Sec., Pres, CEO & Director)

Mr. Augustine J. Lawlor (Chief Operating Officer)

Dr. Cynthia A. Sirard (Chief Medical Officer)

Products/ Services

Biotechnology, Life Science

Headquarters

Cambridge, Massachusetts, United States

Established

2011

Company Registration

SEC CIK number: 0001509745

Traded as

LPTX

Social Media

URL

https://www.leaptx.com

Overview

Location

Recognition and Award

References

Summary

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

History

Leap Therapeutics, Inc. was founded in 2012 to develop innovative therapies to treat some of the toughest cancers. After assembling a world-class life sciences team with deep experience in oncology drug development, the Company has since acquired, developed or in-licensed several clinically and commercially durable compounds, as well as recruited a number of strategic and corporate partners to help bring these treatments to market.

Mission

Our mission is to develop and commercialize targeted and immuno-oncology therapies to improve the lives of cancer patients.

Vision

Our vision is to become a trusted and respected leader in the targeted and immuno-oncology markets with a unique portfolio of innovative treatments and a competitive consumer-oriented commercial strategy.

Key Team

Mr. Mark O'Mahony (Chief Manufacturing Officer)

Ms. Christine M. Granfield (VP and Head of Regulatory Affairs & Quality)

Dr. Jason S. Baum Ph.D. (VP & Head of Translational Medicine)

Dr. Walter Newman (Sr. Research Fellow)

Recognition and Awards

Leap Therapeutics has been recognized for its pioneering work in the oncology space, including being honored with the 2017 Rare Disease Award for Overall Excellence by the Global Genes Project, being named among the 2017 Fierce 15 companies selected by FierceBiotech, and being recognized as a finalist in the 10th Annual Biotech Showcase Awards Program in 2018.